Wounds Pipeline Review and Overview H1 2015

Press Release   •   Aug 25, 2015 09:08 EDT

Wounds - Pipeline Review, H1 2015 Adds “Wounds - Pipeline Review, H1 2015” which provides an overview of the Wounds pipeline.

This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H1, 2015 Pipeline Review of “Wounds” addition with 89 market data tables and 16 figures, spread across 254 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

Advancell, Aerpio Therapeutics, Inc., Agenta Biotechnologies, Inc., AlgiPharma AS, AndroScience Corporation, AnGes MG, Inc., APEIRON Biologics AG, Aridis Pharmaceuticals LLC, Beech Tree Labs, Inc., Bio3 Research S.r.l, Biokine Therapeutics Ltd., Biotec Pharmacon ASA, Birken AG, Blueberry Therapeutics Ltd, Caladrius Biosciences, Inc., Cellphire, Inc., CorMedix, Inc., CYATHUS EXQUIRERE PharmaforschungsGmbH, Destiny Pharma Limited, FibroGen, Inc., Foresee Pharmaceuticals, LLC, GangaGen Inc., Garnet BioTherapeutics, Gene Signal International SA, GlaxoSmithKline Plc, HanAll Biopharma Co., Ltd., IntelliCell BioSciences Inc., Juventas Therapeutics, Inc., Kasiak Research Pvt. Ltd., Kuros Biosurgery AG, LegoChem Biosciences, Inc, Living Cell Technologies Limited, MediWound Ltd., miRagen Therapeutics, Inc., Molecular Design International, Inc., Nabriva Therapeutics AG, NatureWise Biotech & Medicals Corporation, Neumedicines Inc., Novan, Inc., Nuvo Research Inc., Octapharma AG, Omeros Corporation, Omnio Healer AB, Pacific Northwest Biotechnology, LLC, Pergamum AB, Pherecydes Pharma SA, Regenics AS, RXi Pharmaceuticals Corporation, Sanofi, SomaGenics Inc., Stratatech Corporation, Sucampo Pharmaceuticals, Inc., Symic Biomedical, Inc., Thesan Pharmaceuticals, Inc., VBS Pharmaceuticals and Vida Therapeutics Inc.

Drugs Profile Discussed in this Research:

A-3APO, Adipose Stem Cell Therapy for Skin Wound, AG-30/5C, AKB-4924, ALLO-ASC, ANs-31, APN-201, APO-2, Arginine Butyrate, ARN-077, ASCJ-9, Autologous Adipose Stem Cell Therapy for Diabetic Chronic Skin Wound, Autologous Vascular Cells Therapy, BB-1000, BC-7013, Biosimilar for Diabetic Wounds, BKT-170, BTL-slo, CAR Peptide, CaTx-II, Cell Therapy for Wounds, CM-101, cobiprostone, CR-2016, CRMD-004, CTR-2, Cyathus-1102-B, daprodustat, DB-2121, Drug for Dermatology and Infectious Diseases, Drug to Antagonize Beta 2 Receptor for Wound Healing, Drugs to Activate iRhom2 for Wound Healing and Cancer, Drugs to Agonize c-Met for Wound, Drugs to Inhibit 11beta-HSD1 for Wound Healing, EscharEx, FG-6874, FP-009, G-10, GBT-009, Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers, GS-156, HL-156FIB, Human Growth Factor, hVGF, JM-2, JVS-100, KL-7016, KUR-213, LCB-030110, LWnt-3a, MDI-301, Mesenchymal Cells for Wound Care, MGN-4220, MMP-26051, MMP-26052, Monoclonal Antibody Conjugated for Burns and Wounds, Mul-1867, NBM-67, NMIL-121, NTCELL, OleogelS-10, Oligomer G for Wounds And Burns, Oxofoam, P-128, Panaecin, Peptide for Wounds, perflenapent for wound healing, Perlecan, PGF, plasminogen (recombinant), Polysaccharide for Wounds and Scars, PP-0121, PP-1131, Protein for Hematological Disorders, Dermatology, Shock and Injury, Protein for Wounds and Diabetic Complications, Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders, Protein to Inhibit SEB and TSST-1 for Infectious Disease, Dermatology, Respiratory Disorders and Other Diseases, PXL-181, Recombinant Erythropoetin For Wounds, Bone Regeneration and Ulcers, Recombinant Protein to Activate Fibroblast Growth Factor for Wounds, Recombinant Protein to Inhibit Granzyme B for Cardiovascular and Dermatology Diseases, Refaheal, RNAi Oligonucleotide for Wound Healing, RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing, Small Molecule for Chronic Wounds and Burns, Small Molecule to Inhibit MMP-1 and MMP-13 for Wounds, Small Molecule to Target LGR6 for Wound Repair and Formation of New Hair Follicles, Small Molecules for Wounds and Scars, Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology,Soluble Beta Glucan, Stem Cell Therapy for Wound Healing,StrataGraft Skin Tissue, Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders, Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology, Thrombosomes, V-2248, Vasculotide, Vernex, XEN-103 and XF-70

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of Wounds
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Wounds and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Wounds pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products.

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Wounds
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Wound Care Market.

Having a wound can indeed be very painful and it is important that proper would care is ensured. In a normal situation, the outer and inner layers of the skin are in perfect equilibrium and prevent against any kind of external threats. However in case of any abnormal activity like the abrasion or something else, the natural process of healing starts by itself. In fact, there is a natural tendency in the skin to heal by itself over a period of time.

In addition to this, there have been various methods available to help in the wound care. The wound care has continued to evolve over the years from the early days when the use of various herbal products was done to augment the healing. Today, there are various kinds of chemical products available that can really help to increase the healing process and restore the damaged part. It is advised that in case of any wound, proper first aid be provided and then the person should be taken to the nearest doctor to provide him the right treatment. There are in fact a lot of infections that the injured is prone to and the same can be easily avoided by ensuring proper wound care.

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries